Evaluation of the Safety and Efficacy of OnabotulinumtoxinA to the Depressor Anguli Oris

Phase 4 Not yet recruiting 20 enrolled Amir Moradi MD, MBA Allergan · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

Single Center, Double Blind, Placebo- Controlled Study of 20 subjects with 10 active drug/10 placebo Standardized baseline/pre-treatments and follow-up images will be taken. Subjects will receive injection of either study drug or placebo to the Depressor Anguli Oris. Follow ups will occur at 2 weeks, 4 weeks, and 12 weeks.

Timeline

Start: 2020-01
Primary completion: 2020-05
Completion: 2020-07

Publications

Moradi A, Khalifian S, Alghoul MS, Poehler J. A Novel 3-Point Injection Technique for OnabotulinumtoxinA in the Upper Depressor Anguli Oris. Dermatol Surg. 2023 Mar 1;49(3):259-265. doi: 10.1097/DSS.0000000000003695. Epub 2023 Feb 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Botulinum toxin type A	Protein / enzyme biologic	9 iu	Intramuscular

Indications

No indication recorded.